| abstract |
Rituximab for use in a method for the treatment of joint damage in a subject with rheumatoid arthritis (RA), where (a) the subject has presented an inadequate response to one or more inhibitors of anti-tumor necrosis factor (TNF) ; (b) the subject received at least one previous course of treatment with rituximab, and (c) the treatment includes the administration of at least one more course of treatment with rituximab, in which the additional course of treatment is administered 24-40 weeks After the start of the previous course of treatment with rituximab and each course of treatment includes the administration of two intravenous doses of 1000 mg separated 14 days. |